Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.

Blount RJ, Jarlsberg LG, Daly KR, Worodria W, Davis JL, Cattamanchi A, Djawe K, Andama A, Koch J, Walzer PD, Huang L; International HIV-Associated Opportunistic Pneumonias (IHOP) Study.

PLoS One. 2012;7(12):e51545. doi: 10.1371/journal.pone.0051545. Epub 2012 Dec 21.

2.

Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia.

Gingo MR, Lucht L, Daly KR, Djawe K, Palella FJ, Abraham AG, Bream JH, Witt MD, Kingsley LA, Norris KA, Walzer PD, Morris A.

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):190-6. doi: 10.1097/QAI.0b013e3182167516.

3.

Ambient air pollution associated with suppressed serologic responses to Pneumocystis jirovecii in a prospective cohort of HIV-infected patients with Pneumocystis pneumonia.

Blount RJ, Djawe K, Daly KR, Jarlsberg LG, Fong S, Balmes J, Miller RF, Walzer PD, Huang L; International HIV-associated Opportunistic Pneumonias Study.

PLoS One. 2013 Nov 13;8(11):e80795. doi: 10.1371/journal.pone.0080795. eCollection 2013.

4.

Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Daly K, Koch J, Respaldiza N, de la Horra C, Montes-Cano MA, Medrano FJ, Varela JM, Calderon EJ, Walzer PD.

Clin Microbiol Infect. 2009 Oct;15(10):937-42. doi: 10.1111/j.1469-0691.2009.02716.x. Epub 2009 Mar 21.

5.

Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection.

Walzer PD, Djawe K, Levin L, Daly KR, Koch J, Kingsley L, Witt M, Golub ET, Bream JH, Taiwo B, Morris A.

J Infect Dis. 2009 May 1;199(9):1335-44. doi: 10.1086/597803.

6.

Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients.

Blount RJ, Daly KR, Fong S, Chang E, Grieco K, Greene M, Stone S, Balmes J, Miller RF, Walzer PD, Huang L.

PLoS One. 2017 Jul 10;12(7):e0180212. doi: 10.1371/journal.pone.0180212. eCollection 2017.

7.

Antibody responses against Pneumocystis jirovecii in health care workers over time.

Fong S, Daly KR, Tipirneni R, Jarlsberg LG, Djawe K, Koch JV, Swartzman A, Roth B, Walzer PD, Huang L.

Emerg Infect Dis. 2013 Oct;19(10):1612-9. doi: 10.3201/eid1910.121836.

8.

Antibody response to Pneumocystis jirovecii major surface glycoprotein.

Daly KR, Huang L, Morris A, Koch J, Crothers K, Levin L, Eiser S, Satwah S, Zucchi P, Walzer PD.

Emerg Infect Dis. 2006 Aug;12(8):1231-7.

9.

Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients.

Djawe K, Huang L, Daly KR, Levin L, Koch J, Schwartzman A, Fong S, Roth B, Subramanian A, Grieco K, Jarlsberg L, Walzer PD.

PLoS One. 2010 Dec 9;5(12):e14259. doi: 10.1371/journal.pone.0014259.

10.

Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci.

Daly KR, Koch J, Levin L, Walzer PD.

Emerg Infect Dis. 2004 May;10(5):848-54.

11.

Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein.

Djawe K, Daly KR, Vargas SL, Santolaya ME, Ponce CA, Bustamante R, Koch J, Levin L, Walzer PD.

Int J Infect Dis. 2010 Dec;14(12):e1060-6. doi: 10.1016/j.ijid.2010.07.003.

12.

Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons.

Daly KR, Fichtenbaum CJ, Tanaka R, Linke MJ, O'Bert R, Thullen TD, Hui MS, Smulian AG, Walzer PD.

J Infect Dis. 2002 Sep 1;186(5):644-51. Epub 2002 Aug 9.

PMID:
12195351
13.

Humoral immune responses to Pneumocystis jirovecii antigens in HIV-infected and uninfected young children with pneumocystis pneumonia.

Djawe K, Daly KR, Levin L, Zar HJ, Walzer PD.

PLoS One. 2013 Dec 26;8(12):e82783. doi: 10.1371/journal.pone.0082783. eCollection 2013.

14.

Evidence for high prevalence of Pneumocystis jirovecii exposure among Cameroonians.

Nkinin SW, Daly KR, Walzer PD, Ndzi ES, Asonganyi T, Respaldiza N, Medrano FJ, Kaneshiro ES.

Acta Trop. 2009 Nov;112(2):219-24. doi: 10.1016/j.actatropica.2009.07.030. Epub 2009 Aug 7.

15.

Healthcare worker occupation and immune response to Pneumocystis jirovecii.

Tipirneni R, Daly KR, Jarlsberg LG, Koch JV, Swartzman A, Roth BM, Walzer PD, Huang L.

Emerg Infect Dis. 2009 Oct;15(10):1590-7. doi: 10.3201/eid1510.090207.

16.

Serological diagnosis of pneumocystosis: production of a synthetic recombinant antigen for immunodetection of Pneumocystis jirovecii.

Tomás AL, Cardoso F, Esteves F, Matos O.

Sci Rep. 2016 Nov 8;6:36287. doi: 10.1038/srep36287.

17.

Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region.

Mei Q, Turner RE, Sorial V, Klivington D, Angus CW, Kovacs JA.

Infect Immun. 1998 Sep;66(9):4268-73.

18.

IgM response to a human Pneumocystis carinii surface antigen in HIV-infected patients with pulmonary symptoms.

Lundgren B, Kovacs JA, Mathiesen L, Nielsen JO, Lundgren JD.

Scand J Infect Dis. 1993;25(4):515-20.

PMID:
8248753
19.

Discordant antibody and cellular responses to Pneumocystis major surface glycoprotein variants in mice.

Bishop LR, Helman D, Kovacs JA.

BMC Immunol. 2012 Jul 12;13:39. doi: 10.1186/1471-2172-13-39.

20.

Decreased serum antibody responses to recombinant pneumocystis antigens in HIV-infected and uninfected current smokers.

Crothers K, Daly KR, Rimland D, Goetz MB, Gibert CL, Butt AA, Justice AC, Djawe K, Levin L, Walzer PD.

Clin Vaccine Immunol. 2011 Mar;18(3):380-6. doi: 10.1128/CVI.00421-10. Epub 2010 Dec 29.

Supplemental Content

Support Center